Hi {{ session.user.profile.firstName }}

Capsules for Use in Dry Powder Inhalers (DPIs) in Early Phase Dev

Manage webcast
Matt Richardson, Capsugel; Massimo Moratto, Aptuit; Mike Savill, Capsugel
Finding efficient drug delivery methods is becoming increasingly important as the pharmaceutical industry looks to improve the performance of its new compounds and extend the applications of existing drugs. One option that has long been used to successfully treat respiratory conditions and provide compounds with a fast-acting route into circulation is drug delivery via inhalation using a dry powder inhaler (DPI).

Capsugel’s Xcelodose technology is ideally suited to meet the specialized demand for filling capsules for DPI use, as it is proven to dispense very low weights repeatably with precision and accuracy. The technology is suitable for any dry powder, including micronized and cohesive powders, and fills the powder into the capsule without compressing or compacting the powder base, thereby facilitating evacuation on inhalation. Collaborative data shows that the action of filling does not give rise to segregation of blended products provided the constituents have similar particle size and density, nor will it degrade the bonds between API and carrier particles.

Matt Richardson, Pharmaceutical Business Development Manager, Capsugel
Matt has a BS in Chemistry (Wofford College) and Ph.D. (Wake Forest) in synthetic organic and organometallic chemistry. Prior to joining Capsugel in 2005, he worked in process development and scale up of pharmaceuticals.

Massimo Moratto, Senior Scientist Pharmaceutical Development, Aptuit
Massimo has worked in formulation development at Aptuit, formerly GSK, for ten years. He works with solid oral dosage forms, Dry Powder Inhaler formulations and is responsible for upgrading the Aptuit Verona facility for respiratory technologies, including the purchase of a new Xcelodose 600S.

Mike Savill, Pharmaceutical Technology Manager, Capsugel
Mike supports product and process development for Capsugel’s laboratory equipment. He has helped develop the Xcelodose technology and specialises in the automated precision dosing of dry powders.
Jun 28 2011
69 mins
Capsules for Use in Dry Powder Inhalers (DPIs) in Early Phase Dev

Embed in website or blog

Successfully added emails: 0
Remove all
  • Title: Capsules for Use in Dry Powder Inhalers (DPIs) in Early Phase Dev
  • Live at: Jun 28 2011 3:00 pm
  • Presented by: Matt Richardson, Capsugel; Massimo Moratto, Aptuit; Mike Savill, Capsugel
  • From:
Your email has been sent.
or close
You must be logged in to email this